• Jazz repriced and extended its $1.9 billion U.S. dollar term loan, converting Tranche B-2 into a new Tranche B-3.
• Maturity pushed to May 5, 2033 from May 5, 2028 under Amendment No. 4 to the 2021 credit agreement.
• Margin cut by 50 basis points to 1.75% over Term SOFR or 0.75% over prime; Term SOFR floor set at 0.5%.
• Borrowed an additional USD 273.31 million of Tranche B-3 loans to repay B-2 amounts not converted by lenders.
• Quarterly amortization set at 0.25% of initial principal, with the remaining balance due at maturity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-399425), on September 23, 2026, and is solely responsible for the information contained therein.